Antiestrogens: Future prospects

ONCOLOGY

Volumn 11, Issue 2 SUPPL. 1, 1997, Pages 59-64

  Howell, Anthony ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DROLOXIFENE; FULVESTRANT; IDOXIFENE; MIPROXIFENE PHOSPHATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; FUTUROLOGY; HUMAN;

ESTROGEN ANTAGONISTS; FORECASTING; HUMANS; MOLECULAR STRUCTURE; TAMOXIFEN;

EID: 0031005812     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Haddow A, Watkinson JM, Patterson E: Influence of synthetic oestrogens upon advanced malignant disease. Br Med J 2:393-398, 1944.
2. Walpole AL, Patterson E: Synthetic oestrogens in mammary cancer. Lancet 2:783-786, 1949.
3. Cole MP, Jones CTA, Todd IDH: A new anti-oestrogenic agent in late breast cancer: and early clinical appraisal of ICI 146474. Er J Cancer 25:270-275, 1971.
4. Ward HWC: Anti-oestrogen therapy for breast cancer, a trial of tamoxifen at two dose levels. Br Med J 1:13-14, 1973.
5. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15; 71-85, 1992.
6. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer Eur J Cancer 32 A-576-588, 1996.
7. Kangas L: Review of the pharmacological properties of toremifene. J Steroid Biochem 36:191-195, 1990.
8. Kangas L, Niemmen AL, Blanco G, et al: A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17:109-113, 1986.
9. Tomas E, Kauppila A, Blanco G, et al: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59:261-266, 1995.
10. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2256-2566, 1995.
11. Pritchard KI: Summary. Am J Clin Oncol 14(suppl 2):S62-63, 1991.
12. Hasmann M, Rattel B, Loser R: Preclinical data for droloxifene. Cancer Lett 84:101-116, 1994.
13. Eppenberger U, Wosikowski K, Kung W: Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 14 (suppl 2):S5-S14, 1991.
14. Rauschning W and Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31:83-94, 1994.
15. Zhu Ke H, Simmons HA, Pirie CM, et al: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441, 1995.
16. Lindenthal B, Mezger J, von Bergmann K: Tamoxifen and droloxifene lower plasma cholesterol concentrations in postmenopausal women with breast cancer by different mechanisms (abstract). Naunyn-Schmiedeberg's Archiv Pharmacol 353(suppl):R163, 1996.
17. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32:1031-1036, 1983.
18. Fuchs-Young R, Glasebrook AL, Short LL, et al: Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 761:355-360, 1995.
19. Sato M, Rippy MK, Bryant HU: Raloxifene, tamoxifen, nafoxidme, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 10:905-912, 1996
20. Buzdar AU, Marcus C, Holmes F, et al: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45:344-345, 1988
21. Toko T, Matsuo KI, Shibata J, et al: Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors. J Steroid Biochem Mol Biol 43:507-514, 1992.
22. Toko T, Sugimoto Y, Matsuo KI, et al: TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. Eur J Cancer 26:397-404, 1990.
23. Tominaga T, Yoshida Y, Matsumoto A, et al: Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro. Anticancer Res 13:661-666, 1993.
24. Chander SK, McCague R, Luqmani Y, et al: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51:5851-5858, 1991.
25. Coombes RC, Haynes BP, Dowsett M, et al: Idoxifene: Report of a phase I study in patients with metastatic breast cancer. Cancer Res 55:1070-1074, 1995.
26. Parker MG, Arbuckle N, Dauvois S, et al: Structure and function of the estrogen receptor. Ann NY Acad Sci 684:119-126, 1993.
27. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873, 1991.
28. Coopman P, Garcia M, Brunner N, et al: Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells. Int J Cancer 56:295-300, 1994.
29. R-1. Cancer Res 54:1587-1595, 1994.
30. Dowsett M, Howell R, Salter J, et al: Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo. Human Reprod 10:262-267, 1995.
31. Thomas EJ, Wallon PL, Thomas NM, et al: The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Human Reprod 9:1991-1996, 1994.
32. DeFriend DJ, Howell A, Nicholson RI, et al: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408-414, 1994.
33. Howell A, DeFriend D, Robertson J, et al: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345:29-30, 1995.